NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE97393 Query DataSets for GSE97393
Status Public on Jun 25, 2017
Title Gene expression of AML patient samples
Organism Homo sapiens
Experiment type Expression profiling by array
Summary It has been hypothesized that chemotherapy resistant human acute myeloid leukemia (AML) cells are enriched in an immature phenotype, cellular quiescence and leukemic initiating cells (LICs). However, these hypotheses have never been validated completely in vivo. We have developed a physiologically relevant chemotherapeutic approach with cytosine arabinoside AraC using patient-derived xenograft (PDX) models. AraC-treated AML cells are not consistently enriched for either immature cells or quiescent cells. AraC treatment does not enrich for LICs as measured by limiting dilution in secondary transplantations. Rather chemotherapy resistant cells in vivo have high levels of reactive oxygen species (ROS) and a gene signature consistent with oxidative phosphorylation (OXPHOS). Treatment of human HIGH OXPHOS but not LOW OXPHOS AML cell lines showed chemotherapy resistance in vivo, showing that essential mitochondrial functions make significant contributions to AraC resistance in AML. Accordingly, targeting mitochondrial OXPHOS metabolism through the inhibition of mitochondrial protein synthesis, the electron transfer chain or fatty acid oxidation induced an energetic shift towards LOW OXPHOS and strongly enhanced anti-leukemic effects of AraC in AML cells. These results demonstrate that chemotherapy resistance in AML is not necessarily associated with stemness but is highly dependent on a distinct oxidative metabolism, and that the HIGH OXPHOS gene signature is a robust hallmark of the AraC response in PDX and a promising therapeutic avenue to treat AML residual disease.
 
Overall design Human acute myeloid leukemia primary cells from patients were grown during 2 hours for RNA extraction and hybridization on Affymetrix microarrays. We sought to obtain gene signature specific of in vivo response to cytarabine in NSG mice.
 
Contributor(s) Farge T, Larrue C, Danet-Desnoyers G, Carroll M, Récher C, Sarry J, Kaoma T
Citation(s) 28416471
Submission date Apr 04, 2017
Last update date Mar 15, 2019
Contact name Tony KAOMA
E-mail(s) tony.kaoma@lih.lu
Organization name Luxembourg Institute of Health
Department Quantitative Biology Unit
Lab Bioinfo platform
Street address 1 A-B Rue Thomas Edison
City Strassen
ZIP/Postal code L-1445
Country Luxembourg
 
Platforms (1)
GPL16686 [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version]
Samples (21)
GSM2563762 Patient 53
GSM2563763 Patient 262
GSM2563764 Patient 325
Relations
BioProject PRJNA381625

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE97393_RAW.tar 165.0 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap